- Global Pharma News & Resources

[2021] Oncology Drug Pipeline Analysis Market Outlook, Global Demand, Size Estimation, Industry Share, Business Insight, Challenges, Opportunities, Regional Revenue 2026

SEATTLE, April 12, 2021, (PHARMIWEB) — The oncology is branch of medicine that deals with prevention, diagnosis, and treatment of cancer. In the recent past, oncology sector has witnessed rapid growth due to emergence of novel therapies with high efficiency, which is driving growth of the global oncology drug pipeline market. For instance, in 2015, the U.S. Food and Drug Administration (FDA) approved 45 New Molecular Entity (NME) and new Biologic License Applications (BLA), of which 16 were novel cancer therapies. Therefore, developments of novel drugs is a major factor propelling growth of the global oncology drug pipeline analysis market.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @

Furthermore, rising initiatives for reducing cancer-related deaths is expected to boost growth of the market. For instance, in 2017, the World Health Assembly passed a resolution – ‘Cancer Prevention and Control through an Integrated Approach’, which implores governments and the World Health Organization (WHO) to accelerate action for minimizing premature mortality in cancer. Such initiatives are expected to propel growth of the global oncology drug pipeline market in the forecast period.

Market Dynamics-Drivers

Innovative methods applied by research institutes and key players in the market in the cancer treatment is expected to fuel growth of the oncology pipeline drugs market. For instance, the novel basket study focuses on patients with a certain genetic mutation in common, irrespective of the site or origin of cancer in the body. Basket studies are extremely useful when a drug targets certain genetic mutation at a particular site and using that drug to treat same genetic mutation in cancer at another site. For instance, Larotrectinib, a drug of Loxo Oncology, Inc., is currently under review by the U.S. FDA for the treatment of tyrosine kinase mutation by using basket studies. In May 2018, this drugs was approved as Investigational New Drug.

Moreover, combinational therapies have shown promising results are expected to drive growth of the global oncology pipeline drugs market. For instance, Pfizer Inc. is undergoing efficacy and safety study for Avelumab in combination with chemotherapy, followed by maintenance therapy of Avelumab with PARP inhibitor talazoparib in patients with history of untreated advanced ovarian cancer. This study is under clinical phase III trials and is expected to complete by May 2026.

Furthermore, increasing government initiatives to support oncology research is expected to drive growth of market. For instance, in September 2018, U.S. FDA granted over US$ 18 million for new clinical trial research, of which 33% is for rare forms of cancer, including advanced pancreatic cancer, head and neck squamous cell carcinoma, and acute myeloid leukemia. Major companies in the market are involved in various growth strategies such as mergers, agreement, and collaborations, in order to gain competitive edge in the global oncology drug pipeline market. For instance, in February 2018, Merck & Co., Inc. acquired Viralytics Ltd, an Australia-based oncolytic immunotherapies manufacturer, for US$ 394 million, which helped Merck & Co. strengthen it presence in the immuno-oncology market.

Furthermore, in September 2018, Daiichi Sankyo Company, Limited, entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., to examine the combination of Daiichi Sankyo’s investigational Human Epidermal Growth Factor 2 (HER2) targeting antibody drug conjugate DS-8201 and Pembrolizumab. This combinational drug is intended to be used for metastatic breast and non-small cell lung cancers and is under clinical phase II development.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @

Table 1: Few Current oncology drugs Under Clinical Trials:

Class Drug Indication Sponsor Current Status Study Completion
Combination Chemotherapy Gemcitabine,

Cisplatin, and dendritic cytokine-induced killer cell (D-CIK)



Shenzhen Hornetcorn Bio-technology Company, LTD Phase I,


August 2019






ARCAGY/ GINECO Group Phase I, II September 2021
Immunotherapy Anti-MUC1

CAR-T cells

Gastric, ColorectalCancer PersonGen BioTherapeutics (Suzhou) Co., Ltd. Phase I, II November 2018
Immunotherapy Cervical cancer specific CAR-T cells Cervical


Shenzhen Geno-Immune Medical Institute Phase I, II December 2020
Monoclonal Antibody Cetuximab Colorectal Cancer Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase I November 2018
Antibody-Drug Conjugate Anetumab Ravtansine Pancreatic Cancer Stacey Stein Phase II December 2019

Sources:, Annual Reports, Company Websites

Growing prevalence of cancer has led to increased need for cancer treatment. Furthermore, pharmaceutical companies in the marker are striving to bring new, safe and effective anticancer drugs in the market, which is expected to propel growth of the global oncology drug pipeline analysis market in the near future.

Market Dynamics-Restraints

One of the major factors hindering growth of the market is increasing cost of therapies. For instance, according to a report published in National Center for Biotechnology Information (NCBI), 2016, Pertuzumab-based therapy, used in treatment of HER2 positive breast cancer costs US$ 215,000 per patient.

Moreover, reluctance shown by patients for participation in clinical studies, increase in clinical trial complexity, and resource constraints are some of the other factors restraining growth of the global oncology drug pipeline market. For instance, according to a report published in Journal of Clinical Oncology, June 2012, the rate of number of cancer patients enrolling in clinical trial worldwide is 3%-5% and the rate has not improved since 1980.

Global Oncology Drug Pipeline Analysis – Regional Analysis

Among regions, North America is expected to hold dominant position, in terms of growth in the global oncology drug pipeline market. According to American Cancer Society’s annual report, 2015, although cancer-related death rate in the U.S. has reduced, cancer still remains the second-most common cause of death in the country. Thus, such high prevalence of cancer is expected to drive growth of the oncology drug pipeline market in the region.

Asia Pacific is expected to witness significant growth in the global oncology drug pipeline analysis market. This growth is attributed to increasing prevalence of various types of cancers in the region, especially in emerging economies such as China and India.

Competitive Landscape

Major companies in the market are involved in various growth strategies such as business and capacity expansion, especially in Asia Pacific, in order to enhance their market presence. For instance, in September 2018, BeiGene Co.Ltd., a commercial-stage biotechnology company, selected GE Healthcare’s bio manufacturing facility, ‘KUBio’, for large-scale production of its cancer monoclonal antibodies in China.

Key players operating in the global oncology pipeline drugs market include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Pfizer Inc., AbbVie Inc., Celgene Corporation, Novartis AG, Merck & Co., Inc., Sanofi, Eli Lilly & Co., GlaxoSmithKline, and Amgen Inc.

Global Oncology Drug Pipeline Analysis – Taxonomy

By Drug Class

  • Immunotherapy
  • Monoclonal Antibody
  • Antibody-Drug Conjugate (ADC)
  • Others

By Cancer Type

  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 12-Apr-2021